On April 8, 2021, Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares were offered by Reneo. The shares began trading on the Nasdaq Global Market on April 9, 2021, under the symbol “RPHM.” The underwriters were granted a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price less underwriting discounts and commissions. The offering closed on April 13, 2021.
Wilson Sonsini Goodrich & Rosati advised Reneo on patent matters related to the transaction. The team was led by Val Zunic and included Uale Taotafa, Tyler Baguley, and Mike Hostetler.
For more information, please see Reneo Pharmaceuticals' press release.